Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-02
1998-04-21
Ambrose, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514530, 514729, A61K 31335, A61K 3135, A61K 31045, A61K 31215
Patent
active
057418128
ABSTRACT:
A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering a therapeutically effective amount of a thromboxane ligand which is a compound of formula I, ##STR1## wherein Y is (CH.sub.2).sub.x ; Z is selected from the group consisting of ##STR2## x is an integer of 1 or 2; R.sub.2 is hydrogen or an alkyl radical of from 1 to 4 carbons, A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted or said alkylene or alkenylene may have one or more enchained oxo or imino radicals; B is a methyl radical, a cycloalkyl radical, or an aryl radical, or substituted derivatives of said methyl, cycloalkyl or aryl radicals and X is selected from the group consisting of nitro, cyano, --COOR, --CH.sub.2 OR.sub.1, --C(O)N(R.sub.1).sub.2, --CH.sub.2 N(R.sub.1).sub.2 --CH.dbd.N--OH and --CH.sub.2 SR.sub.1 radicals wherein R is a C.sub.1 to C.sub.10 alkyl, phenyl or benzyl and R.sub.1 is R or hydrogen; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5416106 (1995-05-01), Burk et al.
patent: 5516791 (1996-05-01), Burk et al.
Starr. M.S., "Further Studies on the Effect of Prostalgnadin on Intraocular Pressure in the Rabbit", Exp. Eye Research, 1971, 11, pp. 170-177.
Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents," Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et.al., "PGF.sub.2.alpha. Increases Uveoscleral Outflow", Invest. Ophthalmol. Vis. Sci. (suppl), p. 284, (1987).
Siebold, et.al., "Esterified prostaglandin shows `potent` promise", Prodrug 5 p. 3, (1989).
Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives", Arch. Ophthalmol. 105, p. 1036, (1987).
Coleman, R.A., et al, "Comparison of the Actions of U-46619, A Prostaglandin H.sub.2 -Analogue, with Those of Prostagland H.sub.2 and Thromboxane A.sub.2 on some isolated Smooth Muscle Preparations", Br. J. Pharmacol. 73: pp. 773-778 (1981).
Burk et al; "A Safe and Efficient Method For Conversion of 1,2- and 1,3-Diols to Cyclic Carbonates Utilizing Triphosgene", Tetrahedron Letters, vol. 34, No. 3, pp. 395-398, (1993).
Burk Robert M.
Krauss Achim H.
Woodward David F.
Allergan
Ambrose Michael G.
Baran Robert J.
Lambert Howard R.
Voet Martin A.
LandOfFree
Thromboxane ligands without blood clotting side effects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thromboxane ligands without blood clotting side effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thromboxane ligands without blood clotting side effects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057839